
WA-developed stroke therapy on the world stage
The outcomes of the Australian phase 2 SEANCON clinical trial of the safety and preliminary efficacy of the neuroprotective drug...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Research group
Saumya Heendeniya is a PhD candidate in the Precision Nucleic Acid Therapeutics Research group, led by A/Prof Rakesh N. Veedu, working on mRNA therapeutics. Currently he is working on designing a therapeutic platform for spinal muscular atrophy (SMA).
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.